Gold ekes out gain as focus turns to US tariff negotiations
Spot gold was up 0.4% at $3,334.12 per ounce, as of 0401 GMT. U.S. gold futures edged 0.1% higher to $3,340.90.
"Gold at this moment is consolidating with a slight downward bias, especially with a stronger dollar," said Brian Lan, managing director at GoldSilver Central, Singapore.
"However, many countries are still negotiating with the U.S. on the tariffs. There are still a lot of uncertainties in the market and many are looking for safe havens."
Trump on Saturday threatened to impose a 30% tariff on imports from Mexico and the European Union starting on August 1. However, Trump said on Monday he was open to further negotiations.
U.S. consumer prices increased in June by the most in five months amid higher costs for some goods, suggesting tariffs were starting to have an impact on inflation and potentially keeping the Federal Reserve on the sidelines until September.
Following the data, Trump said that consumer prices were low and the Fed should bring down interest rates now.
The U.S. central bank will probably need to leave rates where they are for a while longer to ensure inflation stays low in the face of upward pressure from the Trump administration's tariffs, Dallas Fed Bank President Lorie Logan said.
Gold, often considered a safe haven during times of economic uncertainties, tends to do well in a low-interest-rate environment.
Market focus now shifts to the U.S. Producer Price Index data due at 1230 GMT on Wednesday for more cues.
Keeping gold's gains in check, the dollar and benchmark U.S. 10-year Treasury yields held near multi-week highs.
Elsewhere, spot silver gained 0.3% to $37.82 per ounce. Platinum rose 0.2% to $1,379.46 and palladium climbed 0.4% to $1,210.66.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
16 minutes ago
- CNBC
AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh
AstraZeneca on Monday said it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs. The Anglo-Swedish biotech company, which is headquartered in Cambridge, England, said the "cornerstone" of the commitment would be a new multi-billion dollar facility to produce its weight management and metabolic portfolio, including its oral GLP-1 obesity pill. The facility, planned for the Commonwealth of Virginia, is set to be AstraZeneca's largest single manufacturing investment in the world and will "leverage AI, automation and data analytics to optimize production," the company said. The latest funding will also expand research and development and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, and create "tens of thousands of jobs," AstraZeneca added. CEO Pascal Soriot said the commitment underpins the firm's "belief in America's innovation in biopharmaceuticals" and would support its ambition to reach $80 billion in annual revenue by 2030, half of which is expected to come from the U.S. AstraZeneca, which made international headlines by developing one of the key Covid-19 vaccines, has long been prioritizing the U.S. market. The United States accounted for over 40% of the company's annual revenues in 2024. In November, shortly after the U.S. presidential election, AstraZeneca announced a $3.5 billion U.S. investment. Earlier this month, The Times reported that the firm may move its listing from London to the U.S., in what analysts said would be a major blow to the U.K.'s public markets. AstraZeneca is the most valuable business listed on London's FTSE 100. The company declined to comment on the Times report. AstraZeneca's funding announcement follows similar moves by global pharmaceutical firms — including Novartis, Sanofi and Roche and U.S.-headquartered Eli Lilly and Johnson & Johnson — who have all vowed over recent months to ramp up their U.S. investment amid U.S. President Donald Trump's demands to reshore domestic manufacturing. The industry is awaiting further clarity on the Trump administration's pharma tariffs, with the final outcome of a Section 232 investigation into the sector due at the end of this month. An effort to rebalance U.S. drug prices with those paid by other countries is also underway. Trump earlier this month suggested that the industry could face levies of up to 200%, with a brief 12-18 month grace period to allow firms to relocate manufacturing stateside. However, many firms and analysts have dubbed the time frame as insufficient. "Typically for most medicines it's a three to four year horizon. We're working very hard to accelerate that as fast as we can and demonstrate we're making the investments we have planned," Novartis CEO Vas Narasimhan said last week during an earnings call, adding that he hoped the administration would make allowances.
Bloomberg
41 minutes ago
- Bloomberg
Malaysia Seeks 20% Trump Tariff But Resists Some US Demands
Malaysia's government is seeking to lower US tariffs threatened by President Donald Trump to about 20%, but is reluctant to meet certain demands around electric vehicles and foreign ownership, according to people familiar with the matter. Prime Minister Anwar Ibrahim's negotiators are seeking a tariff lower than the 25% that takes effect Aug. 1 — aiming for something closer to levels for regional neighbors Indonesia and Vietnam, said the people, who asked not to be identified given the negotiations are ongoing.
CNBC
an hour ago
- CNBC
"We need a common European defense system", says Italy's Elly Schlein
Elly Schlein, Secretary of the Italian Democratic Party discusses President Trump's tariffs, banking consolidation in Italy, European defense spending, and why the EU should sanction Israel as soon as possible.
